The Global Fund expands access to Lenacapavir: iSoS regional partnership to advocate for EECA countries’ inclusion in drug supply plan
Great news in the fight against HIV! On 9 July 2025, the Global Fund announced a historic agreement with Gilead Sciences to ensure access to lenacapavir — a long-acting injectable for pre-exposure prophylaxis (PrEP) — in low- and middle-income countries. This is a true breakthrough: for the first time ever, an innovative HIV prevention product […]